


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO 				Application Number	11/885,362
				Filing Date	Not Assigned
				First Named Inventor	Hillen et al.
				Group Art Unit	Not Assigned
				Examiner Name	Not Assigned
Sheet	1	of	1	Attorney Docket No.	ABB10010P02440US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
		WO 2004/067561	08/12/2004	Abbott GMBH & Co. KG		
		WO 2001/010900	02/15/2001	Univ. of Southern California; Northwestern University		
		WO 1998/033815	08/06/1998	Acumen Pharmaceuticals, Inc.		
Examiner Signature					Date Considered	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		International Society for Neurochemistry, J. Neurochem. Journal of Neurochemistry, 2005, 95, 834-847, Barghorn et al., Globular Amyloid β -peptide ₁₋₄₂ Oligomer - A Homogenous and Stable Neuropathological Protein in Alzheimer's Disease	
		The American Society for Biochemistry and Molecular Biology, Inc. The Journal of Biological Chemistry Vol. 278, No. 13, Issue of March 28, pp. 11612-11622, 2003, 2003, Stine et al., In Vitro Characterization of Conditions for Amyloid- β Peptide Oligomerization and Fibrillogenesis	
		Federation of European Neuroscience Societies. European Journal of Neuroscience, Vol. 13, pp 2015-2024, 2001, Demeester et al., Comparison of the Aggregation Properties, Secondary Structure and Apoptotic Effects of Wild-Type, Flemish and Dutch N-terminally Truncated Amyloid β Peptides	
		The American Society for Biochemistry and Molecular Biology, Inc. The Journal of Biological Chemistry, Vol. 277, No. 35, Issue of August 30, pp 32046-32053, 2002, Dahlgren et al., Oligomeric and Fibrillar Species of Amyloid- β Peptides Differently Affect Neuronal Viability	
		Proceedings of the National Academy of Sciences of USA, Vol. 100, January 7, 2003, pp. 330-335, No. 1, Bitan et al., Amyloid β -protein (A β) Assembly: A β 40 and A β 42 Oligomerize Through Distinct Pathways	
		Elsevier Science Ltd., J. Mol. Biol. (2002) 319, pp. 1279-1290, Wurth et al., Mutations that Reduce Aggregation of the Alzheimer's A β 42 Peptide: an Unbiased Search for the Sequence Determinants of A β Amyloidogenesis	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standards ST.16, if possible. ⁶ Applicant is to place a checkmark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.